Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology.
T-cell engager
anti-drug antibodies
bispecific antibody
immunogenicity
immunotherapy
oncology
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
accepted:
28
03
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
23
4
2022
Statut:
ppublish
Résumé
With increasing numbers of bispecific antibodies (BsAbs) and multispecific products entering the clinic, recent data highlight immunogenicity as an emerging challenge in the development of such novel biologics. This review focuses on the immunogenicity risk assessment (IgRA) of BsAb-based immunotherapies for cancer, highlighting several risk factors that need to be considered. These include the novel scaffolds consisting of bioengineered sequences, the potentially synergistic immunomodulating mechanisms of action (MOAs) from different domains of the BsAb, as well as several other product-related and patient-related factors. In addition, the clinical relevance of anti-drug antibodies (ADAs) against selected BsAbs developed as anticancer agents is reviewed and the advances in our knowledge of tools and strategies for immunogenicity prediction, monitoring, and mitigation are discussed. It is critical to implement a drug-specific IgRA during the early development stage to guide ADA monitoring and risk management strategies. This IgRA may include a combination of several assessment tools to identify drug-specific risks as well as a proactive risk mitigation approach for candidate or format selection during the preclinical stage. The IgRA is an on-going process throughout clinical development. IgRA during the clinical stage may bridge the gap between preclinical immunogenicity prediction and clinical immunogenicity, and retrospectively guide optimization efforts for next-generation BsAbs. This iterative process throughout development may improve the reliability of the IgRA and enable the implementation of effective risk mitigation strategies, laying the foundation for improved clinical success.
Identifiants
pubmed: 35444060
pii: jitc-2021-004225
doi: 10.1136/jitc-2021-004225
pmc: PMC9024276
pii:
doi:
Substances chimiques
Antibodies, Bispecific
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors are employees and shareholders of Amgen Inc.
Références
MAbs. 2019 Jul;11(5):861-869
pubmed: 31099718
Biologicals. 2011 Mar;39(2):100-9
pubmed: 21353596
J Pharm Sci. 2017 Oct;106(10):2946-2954
pubmed: 28576695
Immunotherapy. 2021 Feb;13(2):125-141
pubmed: 33172323
Oncologist. 2020 Mar;25(3):e451-e459
pubmed: 32162804
Clin Cancer Res. 2018 Apr 15;24(8):1816-1823
pubmed: 29549159
Nat Biotechnol. 2007 May;25(5):555-61
pubmed: 17483842
Mol Cancer Ther. 2020 Oct;19(10):2044-2056
pubmed: 32747419
PLoS One. 2018 Apr 3;13(4):e0195325
pubmed: 29614084
AAPS J. 2018 Mar 16;20(3):51
pubmed: 29549534
Arthritis Res Ther. 2010;12(5):217
pubmed: 21029481
AAPS J. 2019 Mar 29;21(3):46
pubmed: 30927117
J Immunother Cancer. 2019 Dec 4;7(1):342
pubmed: 31801624
Dermatol Ther (Heidelb). 2018 Mar;8(1):57-68
pubmed: 29392570
MAbs. 2018 Nov-Dec;10(8):1168-1181
pubmed: 30199322
J Clin Immunol. 2013 Oct;33(7):1192-203
pubmed: 23832582
Front Immunol. 2021 May 05;12:626616
pubmed: 34025638
Gastroenterology. 2019 Nov;157(5):1338-1351.e8
pubmed: 31401142
MAbs. 2017 May/Jun;9(4):680-695
pubmed: 28323513
AAPS J. 2017 Nov;19(6):1587-1592
pubmed: 28971356
Cancer Discov. 2020 Aug;10(8):1194-1209
pubmed: 32414908
J Clin Oncol. 2022 Apr 19;:JCO2101801
pubmed: 35439029
MAbs. 2020 Jan-Dec;12(1):1707418
pubmed: 31924123
J Hematol Oncol. 2015 Aug 01;8:96
pubmed: 26231785
Clin Cancer Res. 2021 May 15;27(10):2669-2671
pubmed: 33692029
Rheumatology (Oxford). 2014 Feb;53(2):213-22
pubmed: 23946436
MAbs. 2015;7(4):662-71
pubmed: 25962087
PLoS One. 2021 Jul 23;16(7):e0254944
pubmed: 34297759
AAPS J. 2016 Nov;18(6):1335-1350
pubmed: 27495119
Ann Rheum Dis. 2017 Oct;76(10):1679-1687
pubmed: 28584187
Clin Cancer Res. 2021 May 15;27(10):2773-2781
pubmed: 33441294
Nat Med. 2021 Jan;27(1):125-135
pubmed: 33432170
Br J Clin Pharmacol. 2010 Jun;69(6):617-25
pubmed: 20565453
Front Immunol. 2020 Apr 21;11:698
pubmed: 32373128
Biologics. 2018 Jan 31;12:37-41
pubmed: 29430171
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33608377
Front Immunol. 2021 Dec 14;12:782788
pubmed: 34970265
J Immunol. 2008 Sep 1;181(5):3183-92
pubmed: 18713989
AAPS J. 2016 Nov;18(6):1439-1452
pubmed: 27450229
AAPS J. 2013 Jul;15(3):852-5
pubmed: 23620231
BioDrugs. 2020 Feb;34(1):39-54
pubmed: 31641991
MAbs. 2022 Jan-Dec;14(1):1993522
pubmed: 34923896
Nat Rev Drug Discov. 2002 Jun;1(6):457-62
pubmed: 12119747
Mol Cancer Ther. 2016 Sep;15(9):2155-65
pubmed: 27406985
J Immunol Methods. 2015 Nov;426:62-9
pubmed: 26255760
Clin Cancer Res. 2017 Sep 15;23(18):5349-5357
pubmed: 28634283
Blood. 2015 Jun 25;125(26):4024-31
pubmed: 25887777
J Immunol Methods. 2016 Apr;431:45-51
pubmed: 26874304
Bioanalysis. 2010 Dec;2(12):1961-9
pubmed: 21110740
Invest New Drugs. 2019 Jun;37(3):461-472
pubmed: 30229512
Am J Hematol. 2020 May;95(5):510-520
pubmed: 32052473
Pharmacol Ther. 2019 Sep;201:103-119
pubmed: 31028837
Arthritis Res Ther. 2018 Jul 27;20(1):155
pubmed: 30053896
MAbs. 2020 Jan-Dec;12(1):1764829
pubmed: 32370596
J Immunol. 1995 Jun 15;154(12):6446-52
pubmed: 7539020
AAPS J. 2017 Nov;19(6):1576-1586
pubmed: 29110222
Cancer Treat Rev. 2010 Oct;36(6):458-67
pubmed: 20347527
J Immunol Methods. 2007 Oct 31;327(1-2):10-7
pubmed: 17716682
J Investig Dermatol Symp Proc. 2007 May;12(1):5-8
pubmed: 17502862
J Immunol Methods. 2014 Jun;408:1-12
pubmed: 24861938
Antib Ther. 2020 Feb 17;3(1):18-62
pubmed: 33928225
Blood. 2020 Nov 19;136(21):2401-2409
pubmed: 32730586
Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8571-6
pubmed: 24799704
Clin Cancer Res. 2018 Apr 1;24(7):1536-1545
pubmed: 29217526
FASEB J. 2011 Jun;25(6):2040-8
pubmed: 21368101
Expert Opin Biol Ther. 2022 Apr;22(4):441-443
pubmed: 35020532
J Immunol Methods. 2015 Apr;419:1-8
pubmed: 25795420
Nat Rev Rheumatol. 2013 Mar;9(3):164-72
pubmed: 23399692
J Pharm Pharmacol. 2018 May;70(5):584-594
pubmed: 28872677
J Immunother Cancer. 2019 Apr 15;7(1):105
pubmed: 30992085
J Clin Oncol. 2021 Jun 20;39(18):1959-1970
pubmed: 33739857
Nat Clin Pract Rheumatol. 2008 Sep;4(9):491-8
pubmed: 18756274
MAbs. 2017 Feb/Mar;9(2):182-212
pubmed: 28071970
N Engl J Med. 1999 Dec 30;341(27):2068-74
pubmed: 10615080
Clin Exp Immunol. 2016 Jan;183(1):102-13
pubmed: 26400440
J Am Acad Dermatol. 2017 Jun;76(6):1093-1102
pubmed: 28291552
Gastroenterology. 2020 Jan;158(1):189-199
pubmed: 31600487
AAPS J. 2017 Mar;19(2):377-385
pubmed: 28083796
Hum Immunol. 1999 Apr;60(4):282-90
pubmed: 10363719
Vaccines (Basel). 2021 Jul 02;9(7):
pubmed: 34358141
Bioanalysis. 2020 Aug;12(15):1071-1085
pubmed: 32735128
Int J Cancer. 2012 May 1;130(9):2195-203
pubmed: 21702044